This is the authors' abstract. We don't add key points for this paper.
In real-world Chinese patients with diverse GTs, Chinese Food and Drug Administration-approved interferon-free DAAs were well tolerated, provided high cure rates (98.0% overall) including GT3a/3b, and led to improvement of liver function.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: